^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

WT1 expression

i
Other names: WT1, WT1 Transcription Factor, Wilms Tumor Protein, Wilms Tumor 1, WT33, NPHS4, WIT-2, AWT1, WAGR, GUD
Entrez ID:
1d
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
P1, N=29, Terminated, Pyramid Biosciences | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
14d
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=29, Terminated, Pyramid Biosciences | N=74 --> 29 | Trial completion date: Jun 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jul 2023; Sponsor terminated development of PBI-200
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
4ms
Wilms Tumor With Raised Serum Alpha-Fetoprotein: Highlighting the Need for Novel Circulating Biomarkers. (PubMed, Pediatr Dev Pathol)
The resection specimen was comprised of ~55% and ~45% stromal and epithelial elements, respectively, with no anaplasia, but immunohistochemistry using AFP staining revealed positive mucinous intestinal epithelium, consistent with the serum AFP observations. The lack of correlation between tumor response and serum AFP levels in this case highlights a more general clinical unmet need to identify WT-specific circulating tumor markers.
Journal
|
WT1 (WT1 Transcription Factor) • AFP (Alpha-fetoprotein) • NCAM1 (Neural cell adhesion molecule 1)
|
WT1 expression • WT1 positive
4ms
Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers. (PubMed, Front Immunol)
The augmented avidity conferred by the binding of two anti-WT1-HLA-A*02:01 Fab arms has only minimal influence on cell killing potency. These findings demonstrate the need for careful examination of key design parameters for the development of next-generation T cell engagers targeting low density TAA-pMHCs on tumor cells.
Journal • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • WT1 (WT1 Transcription Factor)
|
HLA-A*02 • WT1 expression • WT1 positive
4ms
Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms (PubMed, Zhonghua Yi Xue Za Zhi)
It can be utilized as an auxiliary diagnostic indicator for classical MPN staging but is not correlated with the incidence of thrombotic events. Male and positive JAK2 gene mutation are risk factors for thrombotic events in ET patients.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • JAK2 (Janus kinase 2) • WT1 (WT1 Transcription Factor) • CALR (Calreticulin)
|
JAK2 mutation • WT1 expression • WT1 positive
4ms
Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment (ASH 2023)
The selinexor-containing regimens used in this study were either selinexor (35mg/m 2 biw) alone or in combination with other drugs (decitabine, azacytidine, venetoclax, low-dose cytarabine, and CAG (cytarabine, aclarubicin, G-CSF) regimen). Selinexor-containing regimens have been shown to be effective and well tolerated in post-transplant AML/MDS patients with MRD-positive, including those who have failed first-line preemptive treatment.
Clinical • Real-world evidence • Real-world • Post-transplantation
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
|
Venclexta (venetoclax) • cytarabine • azacitidine • Xpovio (selinexor) • decitabine • aclarubicin
4ms
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=74, Active, not recruiting, Pyramid Biosciences | Recruiting --> Active, not recruiting
Enrollment closed
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
4ms
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
5ms
Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov)
P1, N=15, Active, not recruiting, 3D Medicines | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
Enrollment closed • Trial primary completion date
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
|
Zeltherva (galinpepimut-S)
6ms
Single-Cell Transcriptome Atlas in C57BL/6 Mice Encodes Morphological Phenotypes in the Aging Kidneys (KIDNEY WEEK 2023)
In conclusion, the availability of comprehensive kidney morphology and single-cell transcriptome atlas at various developmental stages of C57BL/6 mice would be a new and significant resource for mechanistic investigations and testing of potential therapeutic interventions.
Preclinical
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
8ms
High-grade Serous Carcinoma can Show Squamoid Morphology Mimicking True Squamous Differentiation. (PubMed, Am J Surg Pathol)
In conclusion, HG-SC can on rare occasions show a "squamoid component" mimicking "squamous differentiation." However, the "squamoid component" in HG-SC does not represent true "squamous differentiation." The "squamoid component" is one part of the morphologic spectrum of HG-SC, which should be interpreted carefully for the differential diagnosis of HG-SC and EC. An immunohistochemical panel including p40, p53, p16, and WT1 is a useful adjunct to achieve a correct diagnosis.
Journal
|
ER (Estrogen receptor) • POLE (DNA Polymerase Epsilon) • WT1 (WT1 Transcription Factor) • TP63 (Tumor protein 63)
|
ER positive • POLE mutation • WT1 expression • WT1 positive
12ms
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=11, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated) • CTAG1B (Cancer/testis antigen 1B)
|
WT1 expression • CTAG1B expression • WT1 positive
|
Opdivo (nivolumab)
1year
MORPHOLOGICAL PHENOTYPE ATLAS OF THE KIDNEY IN THE DEVELOPING C57BL/6 MICE (ISN-WCN 2023)
Since different developmental stages have distinct inherent morphological changes which could affect the interpretation of the final results, special attention should be given when selecting the age of C57BL/6 mice for individual settings. The availability of the morphology atlas of the kidney would be a new and significant resource for mechanistic investigations and testing of potential therapeutic interventions.
Preclinical
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
1year
Adapting the pantograph limb: Differential robustness of fore- and hindlimb kinematics against genetically induced perturbation in the neural control networks and its evolutionary implications. (PubMed, Zoology (Jena))
Interestingly, the observed effects are similar to locomotor deficits reported to arise when sensory feedback from proprioceptors or cutaneous receptors is impaired. A putative participation of Wt1 positive dI6 interneurons in sensorimotor integration is therefore considered.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
1year
DIFFERENT RECOVERY PATTERNS OF CMV-SPECIFIC AND WT1-SPECIFIC T CELLS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLO-HSCT: IMPACT OF CMV INFECTION AND LEUKEMIA RELAPSE (EBMT 2023)
Our results support that CMV reactivation, aside from the CMV-CTL reconstitution, could influence WT1-CTL reconstitution after allo-HSCT, thus potentially contributing to the remission/relapse of AML.
Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • WT1 (WT1 Transcription Factor) • BIRC5 (Baculoviral IAP repeat containing 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
HLA-A*02:01 • IFNG expression • WT1 expression • WT1 positive
1year
Overexpression of Plasmalemmal Vesicle-Associated Protein-1 Reflects Glomerular Endothelial Injury in Cases of Proliferative Glomerulonephritis with Monoclonal IgG Deposits. (PubMed, Kidney Int Rep)
8-oxoguanine accumulation was detected in WT1-positive podocytes but not in PV-1-expressing GECs, suggesting GEC-derived podocyte injury in PGNMID. PV-1 overexpression reflects glomerular endothelial injury, which could be associated with podocyte oxidative stress in PGNMID cases.
Journal
|
WT1 (WT1 Transcription Factor) • CAV1 (Caveolin 1) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
WT1 expression • WT1 positive
over1year
Clinical significance of the increased expression of the WT1 gene in peripheral blood of patients with acquired aplastic anemia. (PubMed, EJHaem)
Thus, moderate increases in WT1cns up to 600 are common in AA patients in stable remission. An increase in the WT1cn-change max over 20.0 may portend transformation from AA to MDS.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
over1year
A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers (SITC 2022)
Patients with colorectal and cisplatin-sensitive ovarian cancer must have documented disease progression to 2 prior systemic treatment regimens (CUE-102 will be ≥ 3rd line therapy); patients with Gastric/GEJ, pancreatic and cisplatin-resistant ovarian cancer must have documented disease progression to 1 prior systemic treatment regimens (CUE-102 will be ≥ 2nd line therapy). Results Trial is currently open and enrolling as of June 14, 2022.
Clinical • P1 data
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • IL2 (Interleukin 2)
|
HLA-A*02:01 • WT1 expression • WT1 positive
|
cisplatin • CUE-102
over1year
Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors. (PubMed, Clin Transl Oncol)
DSP-7888 Emulsion can promote both cytotoxic and helper T-cell-mediated immune responses against WT1-positive tumors. Adegramotide enhances CTL numbers, and the CTLs induced by treatment with both nelatimotide and adegramotide are capable of functioning within the immunosuppressive tumor microenvironment. The ability of anti-PD-1 to enhance the antitumor activity of DSP-7888 Emulsion in mice implanted with WT1-positive tumors suggests the potential for synergy.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule)
|
WT1 expression • WT1 positive
|
adegramotide/nelatimotide (DSP-7888)
over1year
Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov)
P1, N=15, Recruiting, 3D Medicines | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024
Enrollment open • Trial completion date
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
|
Zeltherva (galinpepimut-S)
over1year
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
P1, N=52, Recruiting, Cue Biopharma | Not yet recruiting --> Recruiting
Enrollment open
|
WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
WT1 expression • WT1 positive
|
CUE-102
almost2years
Protective effects of tadalafil on damaged podocytes in an adriamycin-induced nephrotic syndrome model. (PubMed, J Pharmacol Sci)
ADR treatment alone increased the permeability of albumin compared with the control. Tadalafil might inhibit kidney injury progression by preventing damage to podocytes and dysfunction of the glomerular filtration barrier.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
|
doxorubicin hydrochloride
almost2years
New P1 trial
|
WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
WT1 expression • WT1 positive
|
CUE-102
almost2years
Chorioamnionitis Causes Kidney Inflammation, Podocyte Damage, and Pro-fibrotic Changes in Fetal Lambs. (PubMed, Front Pediatr)
In addition, this process was associated with podocyte injury and there are markers to support pro-fibrotic changes to the glomerular mesangium. These data suggest a potential important role for antenatal inflammation in the development of preterm-associated kidney disease, which is frequent.
Journal
|
PDGFRB (Platelet Derived Growth Factor Receptor Beta) • TNFA (Tumor Necrosis Factor-Alpha) • WT1 (WT1 Transcription Factor) • IL10 (Interleukin 10) • PDGFB (Platelet Derived Growth Factor Subunit B)
|
WT1 expression • WT1 positive
almost2years
New P1 trial
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
|
Zeltherva (galinpepimut-S)
almost2years
Urinary Podocyte Count as a Potential Routine Laboratory Test for Glomerular Disease: A Novel Method Using Liquid-Based Cytology and Immunoenzyme Staining. (PubMed, Acta Cytol)
Because our urinary podocyte detection method using PDX immunoenzyme staining can be standardized and it detected glomerular disease with high accuracy, it can likely serve as a noninvasive routine laboratory test for various glomerular diseases.
Journal
|
WT1 (WT1 Transcription Factor) • PODXL (Podocalyxin)
|
WT1 expression • WT1 positive
2years
Two ovarian candidate enhancers, identified by time series enhancer RNA analyses, harbor rare genetic variations identified in ovarian insufficiency. (PubMed, Hum Mol Genet)
We compared the chronological expression profiles of ovarian-specific eRNA with expression profiles for each of the ovarian specific genes, yielding two candidate sequences for enhancers of Wnt4 and Rspo1...Further, by sequencing the region in patients with impaired ovarian development in 24 patients, such as POI, gonadal dysgenesis and 46,XX DSD, we identified rare single nucleotide variants in both sequences. Our results demonstrate that combined analysis of the temporal expression profiles of eRNA and mRNA of target genes presents a powerful tool for locating cis-element enhancers, and a means of identifying disease-associated sequence variants that lie within non-coding regulatory sequences, thus advancing an important unmet need in forward human genetics.
Journal
|
WT1 (WT1 Transcription Factor) • RSPO1 (R-Spondin 1)
|
WT1 expression • WT1 positive
2years
Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma. (PubMed, Gynecol Oncol Rep)
WT1 positivity is observed in over 20% of USC. WT1 expression is associated with improved chemosensitivity which may contribute to improvements in PFS.
Clinical • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
over2years
Acquired Elastotic Hemangioma-like Change of the Vulva Associated With Lichen Sclerosus. (PubMed, Int J Gynecol Pathol)
There is a close link between epidermal hyperplasia and angiogenesis in the formation of this reparative lesion. Recognition of this lesion is crucial to avoid confusion with other significant processes especially Kaposi sarcoma and well-differentiated angiosarcoma.
Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
over2years
[VIRTUAL] Cost-effective immunohistochemical panel for ovarian carcinoma histotype differential diagnostics (ECP 2021)
The developed highly informative IHC panel (WT1, p53, and PR) can be used as a standardized algorithm for determining ovarian carcinoma histotype with 91,7% accuracy. It can improve the detection rate, reduce diagnostic time, facilitate the differential diagnostics and help to choose the optimal treatment option.
HEOR
|
TP53 (Tumor protein P53) • WT1 (WT1 Transcription Factor) • PAX8 (Paired box 8)
|
TP53 mutation • TP53 expression • WT1 expression • WT1 positive
over2years
Automated detection and quantification of Wilms' Tumor 1-positive cells in murine diabetic kidney disease. (PubMed, Proc SPIE Int Soc Opt Eng)
Additionally, our algorithm performed with a higher Cohen's kappa (0.85) than the average manual identification by three renal pathologists (0.78). We propose that this pipeline will enable accurate detection of WT1-positive cells in research applications.
Preclinical • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
over2years
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=20 --> 11 | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated) • CTAG1B (Cancer/testis antigen 1B)
|
WT1 expression • CTAG1B expression • WT1 positive
|
Opdivo (nivolumab) • Zeltherva (galinpepimut-S)
over2years
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=74, Recruiting, Pyramid Biosciences | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
almost3years
[VIRTUAL] Uterine serous carcinoma mimicking advanced ovarian cancer – are there any clues to pre-operative diagnostic differentiation? A mini case series from a cancer centre. (BGCS 2021)
We suggest that in disseminated serous carcinoma with negative WT1 or focal/weak positivity pre-operative hysteroscopy/biopsy is considered. Whilst this may not always alter management, for patients on the border of suitability for primary surgery a preparedness to exert maximal surgical effort may be favoured on identifying USC.
Clinical
|
WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated)
|
MUC16 elevation • WT1 expression • WT1 positive
almost3years
EWSR1-WT1 gene fusions in neoplasms other than desmoplastic small round cell tumor: a report of three unusual tumors involving the female genital tract and review of the literature. (PubMed, Mod Pathol)
In combination with previous reports, our findings suggest pleiotropy of the EWSR1-WT1 fusion is possible and not limited to DSRCT. Subsets of non-DSRCT EWSR1-WT1 positive tumors may represent discrete entities, but further study is necessary.
Review • Journal
|
ER (Estrogen receptor) • WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • MME (Membrane Metalloendopeptidase)
|
WT1 expression • EWSR1-WT1 fusion • WT1 positive
almost3years
Clinical • New P1/2 trial
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
WT1 expression • NTRK positive • NTRK fusion • WT1 positive
|
PBI-200
almost3years
WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms. (PubMed, Int J Gynecol Pathol)
We also stress that a panel of markers should always be used rather than relying on a single marker and that when the morphology is classical of an endometrioid carcinoma, diagnostic immunohistochemistry is not needed given the potential for confusion in cases showing "aberrant" staining. We also discuss the phenomenon of "aberrant" immunohistochemical staining in endometrioid carcinomas which appears more common than in other ovarian carcinomas.
Clinical • Journal
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive
3years
[VIRTUAL] WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13 (CROI 2021)
WT1 is overexpressed in Kaposi sarcoma and is upregulated by vFLIP/K13. Our data demonstrate increased binding of WT1 overexpressing endothelial cells by ESK-1, a human monoclonal antibody in preclinical development as adjuvant immunotherapy directed towards WT1 overexpressing malignancies. Immunotherapy directed towards WT1 may prove as a new treatment strategy in KS.
IO biomarker
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule)
|
WT1 expression • WT1 positive
3years
[VIRTUAL] WT1 Expression in Uterine Serous Carcinoma is Associated with Increased Chemosensitivity and Improved Progression-Free Survival in Afro-Caribbean Women (USCAP 2021)
WT1 positivity is observed in over 20% of USCs in Afro-Caribbean women, limiting its utility as a marker for differentiating between USC and OSC in this patient population. WT1 expression in USC is associated with improved chemosensitivity and longer PFS in this demographic. Our study suggests that WT1 may be a predictive marker for USCs in certain patient populations.
Clinical
|
WT1 (WT1 Transcription Factor)
|
WT1 expression • WT1 positive